Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr 20;10(8):e020286.
doi: 10.1161/JAHA.121.020286. Epub 2021 Apr 13.

The Liver and the Cardiovascular System: Two of a Kind?

Sven Francque  1   2   3
Affiliations
Editorial

The Liver and the Cardiovascular System: Two of a Kind?

Sven Francque. J Am Heart Assoc. .
No abstract available

Keywords: Editorials; cardiovascular disease; liver; metabolic syndrome; non‐alcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

Dr Francque has a senior clinical research mandate from the Fund for Scientific Research Flanders (1802154N) and has acted as advisor and/or lecturer for Roche, Gilead, Abbvie, Bayer, BMS, MSD, Janssen, Actelion, Astellas, Genfit, Inventiva, Intercept, Genentech, Galmed, Promethera, Coherus, and NGM Bio.

Figures

Figure 1
Figure 1. Summary of potential pathophysiological mechanisms responsible for increased cardiovascular disease (CVD) in nonalcoholic fatty liver disease (NAFLD).
NAFLD drives multiple mechanisms that ultimately lead to CVD. These mechanisms are summarized in this figure. Genetic background, adipose tissue, and the gut all contribute, in part via the liver (direct effects also exist but are not within the scope of this review). Structural alterations of the cardiovascular system are marked in red. ANGPTL indicates angiopoietin‐like protein; FetA, fetuin‐A; FGF21, fibroblast growth factor 21; GIP, gastric inhibitory peptide; GLP‐1, glucagon‐like peptide 1; HDL, high‐density lipoprotein; HMGB‐1, high‐mobility group box 1; hs‐CRP, high‐sensitivity C‐reactive protein; IL‐1β, interleukin 1β; IL‐6, interleukin 6; LDL, low‐density lipoprotein; M1/M2, macrophage phenotype 1/2 ratio; OxLDL, oxidized LDL; PAI‐1, plasminogen activator inhibitor 1; PNPLA3, patatin‐like phospholipase domain containing protein 3; sdLDL, small dense LDL; SeP, selenoprotein P; SNP, single‐nucleotide polymorphism; TG, triglycerides; TM6SF2, transmembrane 6 superfamily member 2; TMA, trimethylamine; TMAO, trimethylamine‐N‐oxide; TNF‐α, tumor necrosis factor α; VEGF, vascular endothelial growth factor; and VLDL, very‐LDL. Reproduced from Francque et al 6 with permission. Copyright ©Elsevier, 2016.
See this image and copyright information in PMC

Comment on

References

    1. Estes C, Anstee QM, Arias‐Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904. DOI: 10.1016/j.jhep.2018.05.036. - DOI - PubMed
    1. Huang DQ, El‐Serag HB, Loomba R. Global epidemiology of NAFLD‐related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020. Dec 21. [epub ahead pf print]. DOI: 10.1038/s41575-020-00381-6. - DOI - PMC - PubMed
    1. Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425–439. DOI: 10.1038/s41575-018-0010-0. - DOI - PubMed
    1. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1:312–328. DOI: 10.1016/j.jhepr.2019.07.002. - DOI - PMC - PubMed
    1. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis. 2016;48:105–111. DOI: 10.1016/j.dld.2015.10.016. - DOI - PubMed